Modafinil, Sleep, and Cognition in Cocaine Dependence

Conditions

Cocaine Dependence | Substance-induced Cognitive Disorder | Substance-induced Sleep Disorder

Trial Phase

N/A

Trial Purpose and Description

Trial Purpose

Subjects participating in this protocol will participate in three phases: 1) pre-admission, 2) inpatient admission, and 3) follow-up. Pre-admission involves screening (detailed in inclusion/exclusion criteria section) and one week of outpatient sleep and activity monitoring. Inpatient admission is 16 consecutive nights on the Clinical Neuroscience Research Unit and involves subjective and objective tests of sleep, sleepiness, attention, and learning. During inpatient admission subjects will take modafinil or placebo. For follow-up, subjects will return to the CNRU for one night and again participate in objective tests of sleep, sleepiness, attention, and learning. We hypothesize that modafinil will decrease subject and objective measures of sleepiness and will promote attention and learning in cocaine dependent persons.


Trial Description

A relatively new treatment for the excessive daytime sleepiness (EDS) associated with inadequate sleep is the drug modafinil. Modafinil decreases subjective reports and objective measures of daytime sleepiness under conditions of sleep restriction, while enhancing cognitive performance. At the same time, sleep quality does not appear to be affected significantly. Interestingly, recent clinical trials in cocaine-dependent populations suggest that modafinil reduces the relapse to cocaine use, by unknown mechanisms.

We propose to employ both subjective and objective measures of nocturnal sleep and daytime sleepiness, as well as measures of general cognitive performance and sleep-dependent memory consolidation, to explore potential mechanistic relationships between cocaine abstinence, EDS, and modafinil's efficacy in preventing cocaine relapse.

The following specific aims are proposed:

Specific Aim 1: To establish whether objective measures of poor nocturnal sleep (e.g., reduced total sleep time and sleep efficiency) that progressively characterize periods of sustained cocaine abstinence are also associated with objective evidence of excessive daytime sleepiness (EDS).

Specific Aim 2: To establish the ability of modafinil to reverse the excessive daytime sleepiness (EDS) and deficits in cognitive performance that characterize cocaine abstinence.

Specific Aim 3: To conduct a pilot study to determine whether the observed abnormalities in objective sleep, EDS, and/or cognitive function predict relapse to cocaine use and/or whether successful abstinence from cocaine is associated with normalization of the same.


Participation Guidelines

Age:
18 Years - 65 Years
Gender:
Both

Eligibility Criteria

Inclusion Criteria:

  • Male or female individuals, ages 18-65, meeting current DSM-IV criteria for cocaine dependence. Documented positive urine toxicology screen for cocaine at intake and regular 3 times more weekly use of cocaine.
  • Subject has voluntarily given informed consent and signed the informed consent document(s).
  • Able to read English and complete study evaluations.

Exclusion Criteria:

  • Use of prescription medication in the past 6 months indicating a medical or psychiatric condition that in the opinion of the PI would interfere with study participation (e.g. hypertension, severe renal or hepatic disease, HIV, primary psychotic disorder, primary mood disorder, primary sleep disorder).
  • Meeting DSM-IV criteria for dependence on any substance other than cocaine and nicotine.
  • Significant underlying medical or psychiatric conditions or hypersensitivity to modafinil that in the opinion of the PI would interfere with study participation.
  • Abstinence from cocaine for more than one week prior to inpatient admission.
  • Positive urine or serum pregnancy test.
  • Women who are pregnant or lactating, or not using a reliable method of birth control.
  • (For subjects completing the fMRI portion of the study) Presence of or history indicative of ferromagnetic metal in their bodies.
Sponsor:
National Institute on Drug Abuse (NIDA)
Yale University
Dates:
August 2006
Last Updated:
September 6, 2012
Study HIC#:
0607001659

Clinicaltrials.gov ID: NCT00582491